Published in Lancet on March 03, 2007
Eurartesim® in Patients With Imported Uncomplicated Plasmodium Vivax Malaria | NCT02110784
Vivax malaria: neglected and not benign. Am J Trop Med Hyg (2007) 10.16
Multidrug-resistant Plasmodium vivax associated with severe and fatal malaria: a prospective study in Papua, Indonesia. PLoS Med (2008) 6.61
Plasmodium vivax and mixed infections are associated with severe malaria in children: a prospective cohort study from Papua New Guinea. PLoS Med (2008) 5.29
Epidemiology and infectivity of Plasmodium falciparum and Plasmodium vivax gametocytes in relation to malaria control and elimination. Clin Microbiol Rev (2011) 5.15
Global extent of chloroquine-resistant Plasmodium vivax: a systematic review and meta-analysis. Lancet Infect Dis (2014) 4.09
Determinants of relapse periodicity in Plasmodium vivax malaria. Malar J (2011) 4.00
Artemisinin-based combination therapies: a vital tool in efforts to eliminate malaria. Nat Rev Microbiol (2009) 3.84
Resistance to therapies for infection by Plasmodium vivax. Clin Microbiol Rev (2009) 3.41
Dihydroartemisinin-piperaquine versus artesunate-amodiaquine: superior efficacy and posttreatment prophylaxis against multidrug-resistant Plasmodium falciparum and Plasmodium vivax malaria. Clin Infect Dis (2007) 3.27
Impaired nitric oxide bioavailability and L-arginine reversible endothelial dysfunction in adults with falciparum malaria. J Exp Med (2007) 3.13
Efficacy of dihydroartemisinin-piperaquine for treatment of uncomplicated Plasmodium falciparum and Plasmodium vivax in Cambodia, 2008 to 2010. Antimicrob Agents Chemother (2012) 3.12
Artemisinin combination therapy for vivax malaria. Lancet Infect Dis (2010) 3.08
Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open-label randomised trial. Lancet Infect Dis (2010) 3.08
Adverse pregnancy outcomes in an area where multidrug-resistant plasmodium vivax and Plasmodium falciparum infections are endemic. Clin Infect Dis (2008) 3.01
Angiopoietin-2 is associated with decreased endothelial nitric oxide and poor clinical outcome in severe falciparum malaria. Proc Natl Acad Sci U S A (2008) 2.80
Deployment of ACT antimalarials for treatment of malaria: challenges and opportunities. Malar J (2008) 2.78
Determinants of in vitro drug susceptibility testing of Plasmodium vivax. Antimicrob Agents Chemother (2008) 2.77
Large-scale malaria survey in Cambodia: novel insights on species distribution and risk factors. Malar J (2007) 2.75
Chloroquine resistant Plasmodium vivax: in vitro characterisation and association with molecular polymorphisms. PLoS One (2007) 2.66
Dihydroartemisinin-piperaquine and artemether-lumefantrine for treating uncomplicated malaria in African children: a randomised, non-inferiority trial. PLoS One (2009) 2.43
A head-to-head comparison of four artemisinin-based combinations for treating uncomplicated malaria in African children: a randomized trial. PLoS Med (2011) 2.37
Population pharmacokinetics of piperaquine after two different treatment regimens with dihydroartemisinin-piperaquine in patients with Plasmodium falciparum malaria in Thailand. Antimicrob Agents Chemother (2008) 2.23
Plasmodium vivax recurrence following falciparum and mixed species malaria: risk factors and effect of antimalarial kinetics. Clin Infect Dis (2011) 2.16
Vivax malaria: a major cause of morbidity in early infancy. Clin Infect Dis (2009) 2.15
Clinical and pharmacological determinants of the therapeutic response to dihydroartemisinin-piperaquine for drug-resistant malaria. Antimicrob Agents Chemother (2007) 2.02
Amplification of pvmdr1 associated with multidrug-resistant Plasmodium vivax. J Infect Dis (2008) 1.96
Amodiaquine-artesunate vs artemether-lumefantrine for uncomplicated malaria in Ghanaian children: a randomized efficacy and safety trial with one year follow-up. Malar J (2008) 1.86
The anaemia of Plasmodium vivax malaria. Malar J (2012) 1.82
Geographical variation in Plasmodium vivax relapse. Malar J (2014) 1.73
In vitro activity of pyronaridine against multidrug-resistant Plasmodium falciparum and Plasmodium vivax. Antimicrob Agents Chemother (2010) 1.70
Severe vivax malaria: newly recognised or rediscovered. PLoS Med (2008) 1.65
The effect of dosing regimens on the antimalarial efficacy of dihydroartemisinin-piperaquine: a pooled analysis of individual patient data. PLoS Med (2013) 1.64
Dihydroartemisinin-piperaquine versus chloroquine in the treatment of Plasmodium vivax malaria in Thailand: a randomized controlled trial. Clin Infect Dis (2011) 1.64
Primaquine radical cure of Plasmodium vivax: a critical review of the literature. Malar J (2012) 1.61
The clinical efficacy of artemether/lumefantrine (Coartem). Malar J (2009) 1.52
Selection of known Plasmodium falciparum resistance-mediating polymorphisms by artemether-lumefantrine and amodiaquine-sulfadoxine-pyrimethamine but not dihydroartemisinin-piperaquine in Burkina Faso. Antimicrob Agents Chemother (2010) 1.49
An open-label, randomised study of dihydroartemisinin-piperaquine versus artesunate-mefloquine for falciparum malaria in Asia. PLoS One (2010) 1.48
Parasite-dependent expansion of TNF receptor II-positive regulatory T cells with enhanced suppressive activity in adults with severe malaria. PLoS Pathog (2009) 1.46
Protective efficacy of malaria case management and intermittent preventive treatment for preventing malaria mortality in children: a systematic review for the Lives Saved Tool. BMC Public Health (2011) 1.46
Efficacy and safety of artemether-lumefantrine in the treatment of acute, uncomplicated Plasmodium falciparum malaria: a pooled analysis. Am J Trop Med Hyg (2011) 1.44
Dihydroartemisinin-piperaquine for treating uncomplicated Plasmodium falciparum malaria. Cochrane Database Syst Rev (2014) 1.38
Safety and efficacy of dihydroartemisinin-piperaquine versus artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Zambian children. Malar J (2011) 1.38
Dihydroartemisinin-piperaquine versus chloroquine to treat vivax malaria in Afghanistan: an open randomized, non-inferiority, trial. Malar J (2010) 1.35
Recovery of endothelial function in severe falciparum malaria: relationship with improvement in plasma L-arginine and blood lactate concentrations. J Infect Dis (2008) 1.26
Confirmed vivax resistance to chloroquine and effectiveness of artemether-lumefantrine for the treatment of vivax malaria in Ethiopia. Am J Trop Med Hyg (2011) 1.23
Safety and efficacy of methylene blue combined with artesunate or amodiaquine for uncomplicated falciparum malaria: a randomized controlled trial from Burkina Faso. PLoS One (2008) 1.22
Phenotypic and genotypic characterisation of drug-resistant Plasmodium vivax. Trends Parasitol (2012) 1.17
Plasmodium vivax treatments: what are we looking for? Curr Opin Infect Dis (2011) 1.16
Pharmacokinetics and ex vivo pharmacodynamic antimalarial activity of dihydroartemisinin-piperaquine in patients with uncomplicated falciparum malaria in Vietnam. Antimicrob Agents Chemother (2009) 1.14
Malaria control in Timor-Leste during a period of political instability: what lessons can be learned? Confl Health (2009) 1.14
Safety profile of Coartem: the evidence base. Malar J (2009) 1.09
Pyronaridine-artesunate granules versus artemether-lumefantrine crushed tablets in children with Plasmodium falciparum malaria: a randomized controlled trial. Malar J (2012) 1.08
Dihydroartemisinin-piperaquine treatment of multidrug resistant falciparum and vivax malaria in pregnancy. PLoS One (2014) 1.08
Pharmacokinetic predictors for recurrent malaria after dihydroartemisinin-piperaquine treatment of uncomplicated malaria in Ugandan infants. J Infect Dis (2013) 1.07
Pharmacokinetics, pharmacodynamics, and allometric scaling of chloroquine in a murine malaria model. Antimicrob Agents Chemother (2011) 1.06
Characterization of treatment failure in efficacy trials of drugs against Plasmodium vivax by genotyping neutral and drug resistance-associated markers. Antimicrob Agents Chemother (2011) 1.06
In vivo efficacy of artemether-lumefantrine and chloroquine against Plasmodium vivax: a randomized open label trial in central Ethiopia. PLoS One (2013) 1.06
Gametocyte dynamics and the role of drugs in reducing the transmission potential of Plasmodium vivax. J Infect Dis (2013) 1.03
In vivo and in vitro efficacy of amodiaquine monotherapy for treatment of infection by chloroquine-resistant Plasmodium vivax. Antimicrob Agents Chemother (2008) 1.03
In vivo efficacy of artemether-lumefantrine against uncomplicated Plasmodium falciparum malaria in Central Ethiopia. Malar J (2011) 1.03
Pharmacokinetics and bioequivalence evaluation of two fixed-dose tablet formulations of dihydroartemisinin and piperaquine in Vietnamese subjects. Antimicrob Agents Chemother (2008) 1.02
JPC-2997, a new aminomethylphenol with high in vitro and in vivo antimalarial activities against blood stages of Plasmodium. Antimicrob Agents Chemother (2014) 1.01
Efficacy and safety of artemisinin-naphthoquine versus dihydroartemisinin-piperaquine in adult patients with uncomplicated malaria: a multi-centre study in Indonesia. Malar J (2012) 1.01
Effect of nutritional status on response to treatment with artemisinin-based combination therapy in young Ugandan children with malaria. Antimicrob Agents Chemother (2011) 1.00
Mortality attributable to Plasmodium vivax malaria: a clinical audit from Papua, Indonesia. BMC Med (2014) 0.98
Ex vivo drug susceptibility of ferroquine against chloroquine-resistant isolates of Plasmodium falciparum and P. vivax. Antimicrob Agents Chemother (2011) 0.96
The use of artemether-lumefantrine for the treatment of uncomplicated Plasmodium vivax malaria. PLoS Negl Trop Dis (2011) 0.95
Efficacy and safety of artemisinin combination therapy (ACT) for non-falciparum malaria: a systematic review. Malar J (2014) 0.95
Open-label trial with artemether-lumefantrine against uncomplicated Plasmodium falciparum malaria three years after its broad introduction in Jimma Zone, Ethiopia. Malar J (2012) 0.94
Apoptosis and dysfunction of blood dendritic cells in patients with falciparum and vivax malaria. J Exp Med (2013) 0.94
Revisiting the design of phase III clinical trials of antimalarial drugs for uncomplicated Plasmodium falciparum malaria. PLoS Med (2008) 0.94
Update on the efficacy, effectiveness and safety of artemether-lumefantrine combination therapy for treatment of uncomplicated malaria. Ther Clin Risk Manag (2010) 0.93
Pharmacokinetics of piperaquine in pregnant women in Sudan with uncomplicated Plasmodium falciparum malaria. Am J Trop Med Hyg (2012) 0.93
Pharmacokinetics of L-arginine in adults with moderately severe malaria. Antimicrob Agents Chemother (2008) 0.92
Potential of artemisinin-based combination therapies to block malaria transmission. J Infect Dis (2013) 0.92
Research challenges and gaps in malaria knowledge in Papua New Guinea. Acta Trop (2011) 0.92
Population pharmacokinetics of artesunate and dihydroartemisinin during long-term oral administration of artesunate to patients with metastatic breast cancer. Eur J Clin Pharmacol (2014) 0.92
Safety profile of L-arginine infusion in moderately severe falciparum malaria. PLoS One (2008) 0.92
Artemisinin combination therapy for malaria: beyond good efficacy. Clin Infect Dis (2009) 0.92
Pharmacokinetics and pharmacodynamics of piperaquine in a murine malaria model. Antimicrob Agents Chemother (2007) 0.90
Artemisinin-naphthoquine combination versus chloroquine-primaquine to treat vivax malaria: an open-label randomized and non-inferiority trial in Yunnan Province, China. Malar J (2013) 0.90
Efficacy of Artequick versus artesunate-mefloquine in the treatment of acute uncomplicated falciparum malaria in Thailand. Southeast Asian J Trop Med Public Health (2008) 0.90
Management of relapsing Plasmodium vivax malaria. Expert Rev Anti Infect Ther (2016) 0.88
Increased risk of early vomiting among infants and young children treated with dihydroartemisinin-piperaquine compared with artemether-lumefantrine for uncomplicated malaria. Am J Trop Med Hyg (2010) 0.88
Artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria. Ther Clin Risk Manag (2009) 0.88
Severe malarial thrombocytopenia: a risk factor for mortality in Papua, Indonesia. J Infect Dis (2014) 0.86
Population Pharmacokinetics and Antimalarial Pharmacodynamics of Piperaquine in Patients With Plasmodium vivax Malaria in Thailand. CPT Pharmacometrics Syst Pharmacol (2014) 0.84
The effects of ACT treatment and TS prophylaxis on Plasmodium falciparum gametocytemia in a cohort of young Ugandan children. Am J Trop Med Hyg (2013) 0.84
Therapeutic efficacy of artemether-lumefantrine for Plasmodium vivax infections in a prospective study in Guyana. Malar J (2012) 0.82
Efficacy of amodiaquine in the treatment of uncomplicated falciparum malaria in young children of rural north-western Burkina Faso. Malar J (2008) 0.81
Efficacy and safety of dihydroartemisinin-piperaquine for treatment of Plasmodium vivax malaria in endemic countries: meta-analysis of randomized controlled studies. PLoS One (2013) 0.79
Human T cell recognition of the blood stage antigen Plasmodium hypoxanthine guanine xanthine phosphoribosyl transferase (HGXPRT) in acute malaria. Malar J (2009) 0.79
Maximising the public health benefit of antimalarials. Lancet Infect Dis (2010) 0.79
Differential cellular recognition of antigens during acute Plasmodium falciparum and Plasmodium vivax malaria. J Infect Dis (2011) 0.78
Asymptomatic Vivax and Falciparum Parasitaemia with Helminth Co-Infection: Major Risk Factors for Anaemia in Early Life. PLoS One (2016) 0.77
Changing the malaria treatment protocol policy in Timor-Leste: an examination of context, process, and actors' involvement. Health Res Policy Syst (2013) 0.77
Efficacy and Safety of Artesunate-Amodiaquine versus Artemether-Lumefantrine in the Treatment of Uncomplicated Plasmodium falciparum Malaria in Sentinel Sites across Côte d'Ivoire. Malar Res Treat (2015) 0.77
Severe falciparum malaria. World Health Organization, Communicable Diseases Cluster. Trans R Soc Trop Med Hyg (2000) 22.12
Effects of artemisinin derivatives on malaria transmissibility. Lancet (1996) 7.42
Pharmacokinetics and pharmacodynamics of lumefantrine (benflumetol) in acute falciparum malaria. Antimicrob Agents Chemother (2000) 4.77
Application of genetic markers to the identification of recrudescent Plasmodium falciparum infections on the northwestern border of Thailand. Am J Trop Med Hyg (1999) 4.60
Antimalarial drug resistance and combination chemotherapy. Philos Trans R Soc Lond B Biol Sci (1999) 4.52
Plasmodium vivax resistance to chloroquine? Lancet (1989) 4.51
Efficacy and effectiveness of dihydroartemisinin-piperaquine versus artesunate-mefloquine in falciparum malaria: an open-label randomised comparison. Lancet (2006) 3.90
Dihydroartemisinin-piperaquine against multidrug-resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial. Lancet (2004) 3.72
Diagnosis of resistance to chloroquine by Plasmodium vivax: timing of recurrence and whole blood chloroquine levels. Am J Trop Med Hyg (1997) 3.61
Population pharmacokinetics of piperaquine in adults and children with uncomplicated falciparum or vivax malaria. Br J Clin Pharmacol (2004) 3.48
Efficacy and safety of dihydroartemisinin-piperaquine (Artekin) in Cambodian children and adults with uncomplicated falciparum malaria. Clin Infect Dis (2002) 3.40
The assessment of antimalarial drug efficacy. Trends Parasitol (2002) 3.38
Resistance to chloroquine by Plasmodium vivax in Irian Jaya, Indonesia. Am J Trop Med Hyg (1991) 3.31
Therapeutic response of multidrug-resistant Plasmodium falciparum and P. vivax to chloroquine and sulfadoxine-pyrimethamine in southern Papua, Indonesia. Trans R Soc Trop Med Hyg (2006) 3.08
Randomized, controlled dose-optimization studies of dihydroartemisinin-piperaquine for the treatment of uncomplicated multidrug-resistant falciparum malaria in Thailand. J Infect Dis (2004) 2.82
In vivo assessment of drug efficacy against Plasmodium falciparum malaria: duration of follow-up. Antimicrob Agents Chemother (2004) 2.77
Mefloquine is highly efficacious against chloroquine-resistant Plasmodium vivax malaria and Plasmodium falciparum malaria in Papua, Indonesia. Clin Infect Dis (2006) 2.76
Artemether-lumefantrine for the treatment of multidrug-resistant falciparum malaria. Trans R Soc Trop Med Hyg (2000) 2.76
Therapeutic efficacies of artesunate-sulfadoxine-pyrimethamine and chloroquine-sulfadoxine-pyrimethamine in vivax malaria pilot studies: relationship to Plasmodium vivax dhfr mutations. Antimicrob Agents Chemother (2002) 2.52
Very high risk of therapeutic failure with chloroquine for uncomplicated Plasmodium falciparum and P. vivax malaria in Indonesian Papua. Am J Trop Med Hyg (2003) 2.49
Can primaquine therapy for vivax malaria be improved? Trends Parasitol (2003) 2.31
Plasmodium vivax clinically resistant to chloroquine in Colombia. Am J Trop Med Hyg (2001) 2.30
Effects of a high-fat meal on the relative oral bioavailability of piperaquine. Antimicrob Agents Chemother (2005) 2.00
Chloroquine resistant Plasmodium vivax malaria in India. Trop Med Int Health (1996) 1.81
Pitfalls in estimating piperaquine elimination. Antimicrob Agents Chemother (2005) 1.79
The search for effective and sustainable treatments for Plasmodium falciparum malaria in Africa: a model of the selection of resistance by antifolate drugs and their combinations. Am J Trop Med Hyg (2005) 1.70
Radical cure of Chesson strain vivax malaria in man by 7, not 14, days of treatment with primaquine. Am J Trop Med Hyg (1977) 1.64
Emergence of chloroquine-resistant Plasmodium vivax in Myanmar (Burma). Trans R Soc Trop Med Hyg (1994) 1.64
Malaria situation in several villages around Timika, south central Irian Jaya, Indonesia. Southeast Asian J Trop Med Public Health (1998) 1.42
Higher gametocyte prevalence following failure of treatment of Plasmodium falciparum malaria with sulfadoxine-pyrimethamine and the combination of chloroquine plus sulfadoxine-pyrimethamine: implications for progression of anti-folate resistance. Trans R Soc Trop Med Hyg (2002) 1.33
Pharmacokinetics of piperaquine after repeated oral administration of the antimalarial combination CV8 in 12 healthy male subjects. Eur J Clin Pharmacol (2006) 1.31
Vector studies and epidemiology of malaria in Irian Jaya, Indonesia. Southeast Asian J Trop Med Public Health (1980) 1.31
Common west African HLA antigens are associated with protection from severe malaria. Nature (1991) 9.43
Endemic melioidosis in tropical northern Australia: a 10-year prospective study and review of the literature. Clin Infect Dis (2000) 6.06
Plasmodium falciparum antimalarial drug susceptibility on the north-western border of Thailand during five years of extensive use of artesunate-mefloquine. Trans R Soc Trop Med Hyg (2000) 4.63
Dihydroartemisinin-piperaquine versus artesunate-amodiaquine: superior efficacy and posttreatment prophylaxis against multidrug-resistant Plasmodium falciparum and Plasmodium vivax malaria. Clin Infect Dis (2007) 3.27
The epidemiology of melioidosis in Australia and Papua New Guinea. Acta Trop (2000) 3.16
Therapeutic response of multidrug-resistant Plasmodium falciparum and P. vivax to chloroquine and sulfadoxine-pyrimethamine in southern Papua, Indonesia. Trans R Soc Trop Med Hyg (2006) 3.08
Field evaluation of the ICT malaria P.f/P.v immunochromatographic test for detection of Plasmodium falciparum and Plasmodium vivax in patients with a presumptive clinical diagnosis of malaria in eastern Indonesia. J Clin Microbiol (1999) 3.05
Determinants of in vitro drug susceptibility testing of Plasmodium vivax. Antimicrob Agents Chemother (2008) 2.77
Melioidosis: acute and chronic disease, relapse and re-activation. Trans R Soc Trop Med Hyg (2000) 2.71
Mefloquine pharmacokinetic-pharmacodynamic models: implications for dosing and resistance. Antimicrob Agents Chemother (2000) 2.54
A cluster of melioidosis cases from an endemic region is clonal and is linked to the water supply using molecular typing of Burkholderia pseudomallei isolates. Am J Trop Med Hyg (2001) 2.54
Clinical and pharmacological determinants of the therapeutic response to dihydroartemisinin-piperaquine for drug-resistant malaria. Antimicrob Agents Chemother (2007) 2.02
Amplification of pvmdr1 associated with multidrug-resistant Plasmodium vivax. J Infect Dis (2008) 1.96
Persistent ICT malaria P.f/P.v panmalarial and HRP2 antigen reactivity after treatment of Plasmodium falciparum malaria is associated with gametocytemia and results in false-positive diagnoses of Plasmodium vivax in convalescence. J Clin Microbiol (2001) 1.96
Mefloquine compared with doxycycline for the prophylaxis of malaria in Indonesian soldiers. A randomized, double-blind, placebo-controlled trial. Ann Intern Med (1997) 1.95
HLA class I typing by PCR: HLA-B27 and an African B27 subtype. Lancet (1991) 1.86
Survey of resistance to chloroquine by Plasmodium vivax in Indonesia. Trans R Soc Trop Med Hyg (1996) 1.76
In vitro activity of pyronaridine against multidrug-resistant Plasmodium falciparum and Plasmodium vivax. Antimicrob Agents Chemother (2010) 1.70
New antimalarials. A risk-benefit analysis. Drug Saf (1995) 1.60
Malaria prophylaxis using azithromycin: a double-blind, placebo-controlled trial in Irian Jaya, Indonesia. Clin Infect Dis (1999) 1.49
A case-control auditory evaluation of patients treated with artemisinin derivatives for multidrug-resistant Plasmodium falciparum malaria. Am J Trop Med Hyg (2000) 1.43
Cost-effectiveness of artesunate for the treatment of severe malaria. Trop Med Int Health (2009) 1.43
Neurological melioidosis: seven cases from the Northern Territory of Australia. Clin Infect Dis (1992) 1.43
Failure of the 'pan-malarial' antibody of the ICT Malaria P.f/P.v immunochromatographic test to detect symptomatic Plasmodium malariae infection. Trans R Soc Trop Med Hyg (2000) 1.41
Mefloquine in infants and young children. Ann Trop Paediatr (1996) 1.34
Stronger activity of human immunodeficiency virus type 1 protease inhibitors against clinical isolates of Plasmodium vivax than against those of P. falciparum. Antimicrob Agents Chemother (2008) 1.26
Extensive genetic diversity in the HLA class II region of Africans, with a focally predominant allele, DRB1*1304. Proc Natl Acad Sci U S A (1992) 1.20
Pulmonary tuberculosis, impaired lung function, disability and quality of life in a high-burden setting. Int J Tuberc Lung Dis (2009) 1.20
Therapy of uncomplicated falciparum malaria: a randomized trial comparing artesunate plus sulfadoxine-pyrimethamine versus sulfadoxine-pyrimethamine alone in Irian Jaya, Indonesia. Am J Trop Med Hyg (2001) 1.17
Measuring nitric oxide production in human clinical studies. Methods Enzymol (1999) 1.13
A protocol system to satisfy research specific, disease specific, physician specific, and patient specific informational needs. Proc Annu Symp Comput Appl Med Care (1992) 1.12
An alternative method for sputum storage and transport for mycobacterium tuberculosis drug resistance surveys. Int J Tuberc Lung Dis (2006) 1.12
A promoter polymorphism in the gene encoding interleukin-12 p40 (IL12B) is associated with mortality from cerebral malaria and with reduced nitric oxide production. Genes Immun (2002) 1.07
Detection of histidine rich protein 2 and panmalarial ICT Malaria Pf/Pv test antigens after chloroquine treatment of uncomplicated falciparum malaria does not reliably predict treatment outcome in eastern Indonesia. Am J Trop Med Hyg (2001) 1.07
Glycosylphosphatidylinositols in malaria pathogenesis and immunity: potential for therapeutic inhibition and vaccination. Curr Top Microbiol Immunol (2005) 1.05
In vivo and in vitro efficacy of amodiaquine monotherapy for treatment of infection by chloroquine-resistant Plasmodium vivax. Antimicrob Agents Chemother (2008) 1.03
In vivo and in vitro efficacy of chloroquine against Plasmodium malariae and P. ovale in Papua, Indonesia. Antimicrob Agents Chemother (2010) 1.02
Genetic analysis of Plasmodium falciparum infections on the north-western border of Thailand. Trans R Soc Trop Med Hyg (2000) 1.00
Highly effective therapy for maternal malaria associated with a lower risk of vertical transmission. J Infect Dis (2011) 0.98
Nitric oxide synthase type 2 promoter polymorphisms, nitric oxide production, and disease severity in Tanzanian children with malaria. J Infect Dis (1999) 0.98
Paraplegia secondary to Burkholderia pseudomallei myelitis: a case report. Arch Phys Med Rehabil (2001) 0.91
A focus of endemic malaria in central Java. Am J Trop Med Hyg (1996) 0.91
Prolongation of the QTc interval in African children treated for falciparum malaria. Am J Trop Med Hyg (1998) 0.89
In vivo responses to antimalarials by Plasmodium falciparum and Plasmodium vivax from isolated Gag Island off northwest Irian Jaya, Indonesia. Am J Trop Med Hyg (1999) 0.88
Malaria in a nonimmune population after extended chloroquine or primaquine prophylaxis. Am J Trop Med Hyg (1997) 0.86
A public-private partnership for TB control in Timika, Papua Province, Indonesia. Int J Tuberc Lung Dis (2007) 0.86
Will the high rates of post-treatment sexual stage parasitaemia seen in malaria-endemic areas make the optiMAL antigen test unreliable in predicting malaria treatment outcome? Br J Haematol (2001) 0.84
Chloroquine sensitive Plasmodium falciparum and P. vivax in central Java, Indonesia. Trans R Soc Trop Med Hyg (1996) 0.84
Nitrate levels in malaria. Trans R Soc Trop Med Hyg (1997) 0.84
Profound thrombocytopenia due to Plasmodium vivax malaria. Aust N Z J Med (1992) 0.83
Use of cefotaxime for treatment of Acinetobacter infections. Clin Infect Dis (1992) 0.81
A community-based TB drug susceptibility study in Mimika District, Papua Province, Indonesia. Int J Tuberc Lung Dis (2006) 0.81
Seroprevalence of Burkholderia pseudomallei in East Timorese refugees: implications for healthcare in East Timor. Southeast Asian J Trop Med Public Health (2005) 0.81